Autopsy report · NCT00835679
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
Cause of deathNo reason given
Life of this trial
- Registered 10 months before it started.
- Ran for about 1 year 8 months before it stopped.
- 9 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Early Phase 1
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Liver Metastases; Mucinous Adenocarcinoma of the Colon; Mucinous Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Colon
- Interventions
- cetuximab; dasatinib; therapeutic conventional surgery; laboratory biomarker analysis
- Participants
- 9
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.